Trials / Completed
CompletedNCT01956149
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.
Detailed description
65 patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach will be treated with 20mg/m2 Cabazitaxel for a maximum of 6 cycles. Main objective of the study is the Disease Control Rate (DCR) with Cabazitaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabazitaxel | 20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles. |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2017-12-01
- Completion
- 2018-04-04
- First posted
- 2013-10-08
- Last updated
- 2018-04-18
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01956149. Inclusion in this directory is not an endorsement.